Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Tesaro target raised to $202 at RBC Capital Mkts (182.56)RBC Capital Mkts raises their TSRO tgt to $202 from $142. They believe existing and pending ovarian and breast cancer data allows niraparib to be a $2B+ drug, which justifies the majority of current value. What takes value higher is niraparib being differentiated, PARP inhibitors being used sequentially, activity in other cancers, and prolonged treatment durations. Their $202 target reflects some of this optionality and M&A based multiples could approach similar valuation levels.</td> </tr></table>"